Generation of Multicellular Human Primary Endometrial Organoids
October 4th, 2019
11.1K views
A protocol to generate human primary endometrial organoids that consist of epithelial and stromal cells and retain characteristics of the native endometrial tissue is presented. This protocol describes methods from uterine tissue acquisition to the histologic processing of endometrial organoids.
Overview
This article presents a protocol for generating human primary endometrial organoids that mimic the native endometrial tissue. The organoids consist of epithelial and stromal cells, allowing for physiological studies outside the body.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Reproductive Health
Background
- The endometrium undergoes monthly changes in response to hormonal fluctuations.
- Hormonal imbalances can lead to issues such as cancer and infertility.
- Studying the endometrium in vitro can provide insights into these conditions.
- Organoids can replicate the 3D structure and behavior of endometrial tissue.
Purpose of Study
- To develop a method for creating endometrial organoids for research purposes.
- To facilitate the study of hormonal responses and disease mechanisms.
- To enable drug testing in a more physiologically relevant model.
Methods Used
- Acquisition of uterine tissue from human donors.
- Histologic processing to create organoids.
- Culture of organoids to maintain their structural integrity.
- Assessment of organoid characteristics to ensure they mimic native tissue.
Main Results
- Successfully generated organoids that retain key features of endometrial tissue.
- Demonstrated the ability to study hormonal responses in a controlled environment.
- Provided a platform for testing the effects of risk factors for endometrial cancer.
- Highlighted the potential for organoids in drug testing applications.
Conclusions
- The developed protocol allows for the creation of functional endometrial organoids.
- These organoids can be used to study various aspects of endometrial biology.
- Future research can leverage this model to explore therapeutic options for endometrial diseases.
Frequently Asked Questions
What are endometrial organoids?
Endometrial organoids are 3D structures derived from human endometrial tissue that replicate the native tissue's characteristics.
How can organoids be used in research?
Organoids can be used to study hormonal responses, disease mechanisms, and to test the effects of drugs in a controlled environment.
What is the significance of studying the endometrium?
Studying the endometrium is crucial for understanding reproductive health, hormonal imbalances, and diseases such as cancer.
What are the advantages of using organoids over traditional cell cultures?
Organoids better mimic the 3D architecture and cellular interactions found in vivo, providing more relevant physiological data.
Can organoids be used to study cancer risk factors?
Yes, organoids can be utilized to investigate the effects of known cancer risk factors, such as obesity and polycystic ovarian syndrome.
What is the process for creating endometrial organoids?
The process involves acquiring uterine tissue, processing it histologically, and culturing it to form organoids that retain tissue characteristics.
Executive Industry Relevance
This protocol enables the generation of multicellular human primary endometrial organoids that recapitulate native tissue architecture and hormonal responsiveness, addressing a critical gap in physiologically relevant models for reproductive health research. By incorporating both epithelial and stromal cell types in a scaffold-free 3D structure, the model supports mechanistic de-risking of endometrial pathophysiology and provides a translational platform for evaluating hormonal and metabolic risk factors. The system enhances predictive confidence in preclinical studies of endometrial cancer, infertility, and hormone-related disorders, offering enterprise R&D value through improved target validation and assay development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through physiological hormone responses in epithelial and stromal compartments.
- Operational Value: Supports functional target validation by preserving native receptor expression (ER, PR, AR) and paracrine signaling.
- Scientific Value: Facilitates biological de-risking of endometrial pathways by modeling native tissue organization and collagen deposition.
Screening & Assay Development
- Scientific Value: Provides a standardized, reproducible 3D system for quantitative assessment of drug-induced phenotypic changes.
- Operational Value: Enables scalable preparation of organoids for downstream applications such as immunohistochemistry and RNA extraction.
- Scientific Value: Supports assay readiness by maintaining hormonal responsiveness to physiological levels of estradiol and testosterone.
Translational & Preclinical Research
- Scientific Value: Models disease-relevant conditions such as obesity and PCOS through exposure to adipocyte signals and excess testosterone.
- Operational Value: Ensures translational continuity by maintaining endometrial biomarkers and stromal collagen production.
- Scientific Value: Supports predictive confidence in preclinical advancement by recapitulating hormone-driven tissue behavior.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through preclinical evaluation, offering a human-relevant system for studying endometrial biology and disease mechanisms.
- Discovery Biology: Supports hypothesis testing and pathway clarification via hormonally responsive epithelial-stromal interactions.
- Screening: Delivers assay standardization and quantitative outputs through measurable structural and molecular organoid features.
- Analytics: Enables comparative condition analysis via hormone treatment, receptor staining, and collagen deposition readouts.
- Translational Research: Connects discovery to preclinical validation through disease-relevant modeling of hormonal and metabolic risk factors.
- Enterprise Reuse: Establishes a reusable, hormone-responsive platform for iterative compound screening and mechanism-of-action studies.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through physiological hormone responses and native-like tissue organization.
- Operational Value: Standardization and reproducibility via defined cell ratios, agarose molding, and hormone-supplemented culture.
- Strategic Value: Improved go/no-go decisions by reducing late-stage biological risk in endometrial disease models.
- Portfolio Impact: Risk-adjusted prioritization of compounds targeting endometrial pathways based on mechanistic de-risking data.
Implementation Considerations
- Requires expertise in primary tissue isolation, cell straining, and hormone-responsive culture conditions.
- Dependent on access to human endometrial tissue and aseptic biosafety cabinet facilities.
- Necessitates standardized protocols for cell density optimization and agarose mold preparation.
- Involves adaptation considerations for scaling organoid production while maintaining epithelial-stromal ratios.
- Limited by the small size of organoids, which may challenge visualization and downstream processing without optimized techniques.
Biopharma FAQs
Why does hormone treatment matter for endometrial organoid organization?
Treatment with physiological levels of estradiol and testosterone promotes the self-organization of epithelial and stromal cells, enabling the formation of a polarized structure where epithelial cells surround stromal collagen-producing centers, which is essential for modeling native endometrial behavior in drug screening applications.
How does isolating epithelial and stromal cell fractions support target validation?
Separating and recombining epithelial and stromal cells at a 3:1 ratio ensures proper paracrine signaling and tissue-like organization, which is critical for validating targets that depend on stromal-epithelial interactions in endometrial pathophysiology.
What quantitative measurements enable assessment of stromal functionality in organoids?
Trichrome staining quantifies collagen deposition in the organoid center, providing a direct readout of stromal cell activity and extracellular matrix production, which mirrors native endometrial stroma and supports mechanistic de-risking of fibrotic pathways.
Why are replication requirements important for cross-functional collaboration in organoid generation?
Consistent organoid formation across replicates ensures reliable hormone response data, enabling alignment between discovery biology, assay development, and preclinical teams on target engagement and phenotypic readouts.
What statistical analysis capabilities are required before implementing endometrial organoids in screening workflows?
Implementation requires the ability to analyze hormone dose-response curves, receptor expression levels, and collagen quantification data to establish significant differences between control and treatment conditions for go/no-go decisions.
